1. Academic Validation
  2. Combinatorial chemoprevention of intestinal neoplasia

Combinatorial chemoprevention of intestinal neoplasia

  • Nat Med. 2000 Sep;6(9):1024-8. doi: 10.1038/79534.
C J Torrance 1 P E Jackson E Montgomery K W Kinzler B Vogelstein A Wissner M Nunes P Frost C M Discafani
Affiliations

Affiliation

  • 1 The Howard Hughes Medical Institute and The Johns Hopkins Oncology Center, Baltimore, Maryland 21231, USA.
PMID: 10973323 DOI: 10.1038/79534
Abstract

A combination of two drugs afforded remarkable protection from intestinal neoplasia in APC(Min/+) mice, a murine model of human familial adenomatous polyposis (FAP). One of the drugs was sulindac, a prototypical non-steroidal anti-inflammatory drug with established chemopreventative activity. The second drug was EKI-569, a newly developed, irreversible inhibitor of the epidermal growth factor receptor kinase. Although 100% of the untreated APC(Min/+) mice developed approximately 20 polyps, nearly half the mice treated with these two agents developed no polyps at all. These results suggest a powerful strategy for the chemoprevention of human colonic neoplasia.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-32718
    98.80%, Src Inhibitor